Dilemma: Pain and Loss of Control Rendering Anti-Cancer Treatment Helpless
Previously, due to suffering from senile dementia, Ms. Zhao frequently exhibited involuntary speech and body movements during diagnosis and treatment. In several top-tier hospitals within the province, treatment was interrupted because she could not cooperate with interstitial brachytherapy radiotherapy.
Hu Yuefeng, Deputy Chief Physician of the Radiotherapy Third Ward, said, although traditional interstitial brachytherapy radiotherapy can precisely target cancer cells, the pain caused by the insertion needles easily leads to patient resistance to treatment. Especially for special groups like those with senile dementia, pain becomes a “roadblock” to treatment. Moreover, the patient’s uncontrolled behavior could also trigger medical risks.
Solution: Multidisciplinary Knockout Combo:Transforming Treatment from “Enduring Pain” to “Sensation-Free”
At the critical moment, the multidisciplinary team at Hainan Cancer Hospital rapidly assembled! With the strong support of Patient-Controlled Analgesia (PCA) technology from the Pain Management Department, the expert team of the Radiotherapy Third Ward successfully performed non-general anesthesia, painless sedation, 3D interstitial brachytherapy radiotherapy for Ms. Zhao.
(Doctor preparing the patient before treatment)
Zhang Zhichun, Director of the Pain Management Department, introduced that Patient-Controlled Analgesia technology is an intelligent analgesic device, convenient to operate, highly safe, and with minimal side effects. The medical team will precisely preset the analgesic drug dosage based on the patients individual condition. When the patient experiences pain, simply pressing the dedicated analgesic button allows self-administration of medication, achieving “self-managed” pain relief, helping the patient receive treatment in a pain-free state. This technology is particularly widely applied in invasive treatment scenarios like interventional procedures and radiotherapy.
For special patients exhibiting abnormal behavior, medical staff will also administer small doses of sedatives, allowing the patient to enter a light sleep state and smoothly complete the treatment “sensation-free.’
Breakthrough:From “Treatable” to “Treatable Well,” Comfort-Oriented Care Upgraded Again
Luo Yunxiu, Head of the Radiotherapy Third Ward, stated that this non-general anesthesia, painless sedation, 3D interstitial brachytherapy radiotherapy opens a new path of precise and comfortable treatment for special cervical cancer patients.
Since pioneering 3D interstitial brachytherapy technology in 2017, our hospital’s Radiotherapy Third Ward has continuously optimized medical techniques. In 2023, painless brachytherapy technology was introduced. Now, the innovative combination of “non-general anesthesia self-controlled analgesia sedation technology + 3D interstitial brachytherapy treatment” will provide more specialized tumor patients with precise and humanized diagnosis and treatment services, advancing tumor radiotherapy towards “comfort-oriented medicine.”
Radiotherapy Experts
Luo Yunxiu Deputy Head, Radiotherapy Third Ward
Chief Physician Medical Doctor PI
Medical Expertise
Excels in radiotherapy for head and neck tumors(brain/nasopharynx/oropharynx/hypopharynx/larynx/parotid/sinuses/esophagus,etc.); breast cancer, digestive system tumors (liver/pancreas/stomach/rectum/pancreatic head/gallbladder cancer, etc.); urogenital (cervical cancer, prostate cancer, endometrial cancer, kidney cancer); pediatric tumors, soft tissue sarcomas, thoracic tumors, and rare tumors; integrates multi-modal advanced radiotherapy techniques to treat difficult, complex, refractory tumors; possesses rich experience in preventing and treating tumor radiotherapy and chemotherapy complications.
Pain Management Experts
Zhang Zhichun Director, Pain Management Department
Chief Physician
Hainan Provincial High-Level Talent (Other Category)
Medical Expertise
Long-term engagement in the diagnosis and treatment of chronic painful diseases; possesses rich diagnostic and therapeutic experience in cancer pain, chronic pain, and the field of comfort-oriented analgesia.
Excels in the diagnosis and treatment of cancer pain, herpes zoster, headaches, spinal joint, and soft tissue painful diseases.
Drug Clinical Trial Recruitment
Drug clinical trials provide patients with the opportunity to receive the latest treatment methods free of charge, offering new possibilities for patient recovery.
The National Drug Clinical Trial Institution of Hainan Cancer Hospital is currently recruiting subjects such as those with PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
If you or someone around you meets the following criteria and has relevant registration intentions, you can directly contact the relevant project researchers.
1. Project Title: A Randomized, Controlled, Multicenter Phase III Clinical Study of AK112 Combined with AK117 Versus Pembrolizumab as First-Line Treatment for PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2. Indication: PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma
3. Investigational Drugs: AK117 Injection, AK112 Injection
4. Matching Drug: Ligufalimab Ivonescimab
5. Administration Method: Injection; every 3 weeks constitutes one cycle
6. Trial Department: Radiotherapy Third Ward
7. Recruitment Contacts & Phone:
(CRC) Zhou Wanfen: 15120759373
(PI) Luo Yunxiu: 13886114385
Article | Huang Fei